雷帕鸣的作用

It is indicated for patients undergoing kidney transplantation to prevent organ rejection and is recommended for use in combination with cyclosporine and corticosteroids. Treatment with rapamin should be started as soon as possible after transplantation. It should be taken orally. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. Although in clinical trials, it was safe and effective for patients to use a loading dose of 15 mg and a maintenance dose of 5 mg/day, the therapeutic benefit of doses above 2 mg for kidney transplant patients is unclear. The overall safety profile of patients taking 2 mg of rapamide daily was better than that of patients taking 5 mg rapamide daily.

As early as 1999, Rapamin was approved for marketing in the United States. At present, in addition to the original drug, Biocan Rapamide is also on the market in India. Due to its relatively low price, it is very popular among patients in developing countries. So what is the role of Biocan Rapamide in India?

Founded in 1978, Biocon India is one of the three largest biotechnology companies in India. It is an emerging global biopharmaceutical company. The company's research and development focuses on prevention, relief and treatment. Its drugs have improved the lives of millions of patients in more than 120 countries by allowing patients to obtain life-saving treatment and relief.

India's Biocontan Lepamin has the same effect as the original drug, inhibiting the body's immune function by affecting unique cell signaling pathways. Rapamin and FK506 share the same receptor in the body, namely FK506 immune binding protein (FKBP). After rapamin binds to FKBP, on the one hand, it inhibits the activation of 70-KSU6 kinase (p7), preventing the ribosome 40S subunit S6 protein from phosphorylating g7, affecting protein synthesis; on the other hand, it inhibits cyclin D2, D3 and cell cycle-dependent kinase (cdk4). The expression of cdk6 and the activation of Cyclin E-cdk2 complex cause cells to arrest in the middle and late stages of GI and cannot continue to proliferate.

In clinical trials, patients' use effectively reduced the risk of organ rejection and prolonged the patient's survival.

Recommended related hot articles: /newsDetail/86906.html